EN DE
Watch IQVIA Holdings Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

IQVIA Holdings Inc (IQV) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of IQVIA Holdings Inc stock $289, price $265, upside +9.0%, quality 60 out of 100. Rating: fairly valued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

IH IQVIA Holdings Inc logo Some data Nov 4, 2026

IQVIA Holdings Inc

IQV · US
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 60/100
Healthy Growth (revenue 5y +7.5 %/yr in USD)
Generates free cash flow
Ranks above peers (11/13)
Positive coverage
Fair value $288.85 · Fairly valued (+9.0%)
Thin margins · 8.1% net margin (TTM)
Moderate moat 64/100
Insiders sold $29.9M (6M)
Some data
High debt
Quality growth

Risks from the AI analysis

🚩AI automation of clinical trial services🚩Data privacy regulatory actions
Watch IQVIA Holdings Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$282.61 $137.00 Fair Value $288.85 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $137.00 – $282.61 · fair‑value band $178.47 – $402.58 · the $264.88 price screens below the $288.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow IQVIA Holdings in your weekly email

Every Wednesday you see whether IQVIA Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

Show moreShow less

It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.

The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services.

The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.

The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Stock analysis

IQVIA Holdings Inc (IQV) currently trades at $264.88, while our model-based Fair Value estimate is $288.85, so the stock looks roughly fairly valued today (gap 8.3%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $156.47 per share, and 0 of the 22 models we run sit above the $264.88 price.

Bear case: the Economic Profit group reads lowest at $63.56, and 22 of the 22 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $178.47 (bear) to $402.58 (bull), the price of $264.88 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

IQVIA Holdings Inc reported revenue of $16.3B in FY2025 versus $13.9B in FY2021, a compound +4.1%/yr. Reported net income was $1.4B in FY2025, compounding +8.9%/yr from FY2021.

Key figures

Market cap $44.7B Large · P/E ratio 32.2 · P/S ratio 2.58 · EPS (TTM) $8.22 · Net margin 8.1% · Return on equity 21.4% · Return on assets (EBIT) 7.2% · Operating margin 13.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 5% below its 52-week high and 69% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at 9%, IQV screens cheaper than that median.

Fair Value models

Bear $178.47 Fair Value $288.85 Bull $402.58
Price $264.88 · Upside +9.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($6.98 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $108.46 $213.26 $371.14 77
Growth DCF $109.64 $210.92 $360.77 76
Owner Earnings $106.79 $210.62 $367.03 73
All 22 models by family
DCF Models
FCF DCF $108.46 $213.26 $371.14 77
Owner Earnings $106.79 $210.62 $367.03 73
5Y Revenue Exit $70.27 $151.04 $254.39 70
5Y EBITDA Exit $118.26 $243.31 $391.63 73
5Y P/E Exit $70.76 $151.99 $238.27 68
10Y Revenue Exit $78.88 $155.82 $260.64 64
10Y EBITDA Exit $112.70 $219.01 $365.07 66
10Y P/E Exit $82.95 $156.47 $248.38 62
Earnings-Based
Graham-Dodd $56.12 $198.66 $267.39 64
Lynch FV $46.56 $66.51 $86.47 61
PEG = 1.0 $46.56 $66.51 $86.47 57
EPV $38.70 $55.97 $70.83 73
Multiples
P/E Multiple $136.17 $181.55 $226.94 63
P/S Multiple $105.22 $140.29 $175.36 58
EV/EBIT $90.81 $149.79 $208.77 64
EV/EBITDA $132.47 $205.34 $278.21 66
EV/Revenue $40.16 $94.28 $148.40 50
Growth DCF
Growth DCF $109.64 $210.92 $360.77 76
Rev-Margin DCF $70.27 $151.62 $248.87 70
Economic Profit
Residual Income $49.16 $63.56 $104.58 68
ROIC Compounder $38.70 $67.34 $105.88 69
Growth Earnings
Growth-Adj P/E $92.55 $132.22 $171.88 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 43
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 72
Do the profits arrive as real cash?
Financial strength 25
Debt, balance sheet and risk of trouble
Investment 81
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 73
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 75
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors sold shares worth $29.9M and none bought.

  • SaleJames G. BerkshireOfficer2,668 shares at $261.33$697,228Sep 2, 2026
  • SaleW Richard StaubOfficer5,500 shares at $232.68$1.3MAug 3, 2026
  • SaleBhavik PatelOfficer1,855 shares at $235.27$436,426Jul 31, 2026
  • SaleAri BousbibOfficer, Director2× since Dec 18, 2025: 142,843 shares, avg. $239.60$34.2MJul 29, 2026
  • SaleKeriann CherofskyOfficer558 shares at $245.21$136,827Jul 29, 2026
  • SaleEric SherbetOfficer5,000 shares at $249.16$1.2MJul 29, 2026

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Start year 2020 (pandemic). Over 10 years: +11.0% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+40.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+40.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.40.5% vs 11.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 14%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +13.2% a year for the price and +3.4% for the forecasts.
Forecast 2026 (sales)+7.1%
Forecast 2027 (sales)+6.4%
Projected 2028 (sales)+5.9%
Projected 2029 (sales)+5.3%
Projected 2030 (sales)+4.8%

Watch IQV, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Moderate moat from scale in clinical research services and data capabilities is offset by high leverage with elevated total debt relative to equity.
Main risk: Generative AI and agentic tools could automate labor-intensive tasks such as site monitoring, data cleaning and regulatory writing in clinical trials, reducing billable hours and squeezing margins in IQVIA's research and development solutions segment.
Bull case: IQVIA could integrate its proprietary datasets with custom agentic AI models to deliver higher-value automated insights that clients cannot easily replicate in-house, strengthening demand for its integrated services.
Bear case: Widespread AI automation of trial operations combined with tighter data privacy rules could erode the need for IQVIA's traditional data aggregation and labor-based CRO services, shrinking its addressable market.
IQVIA's new Explorer and Life Science Models turn weeks-long commercial and trial analyses into tasks completed in minutes by combining its data with AI workflows. This builds directly on its role supplying insights to life sciences firms, yet it also invites faster replication by competitors who already hold large datasets. Our models see the shares as undervalued, but will the speed advantage strengthen client lock-in or simply compress margins across the sector?
Join the discussion →

Compare IQVIA Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 60 · Above median
Fair Value upside +9.0% · Above median
Profitability
Return on equity (12 months) 21.4% · Top 25%
Return on assets 4.5% · Above median
Net margin (12 months) 8.1% · Above median
Operating margin (12 months) 13.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) 8.0% · Above median
Balance sheet
Debt / equity 2.14× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 32.2× · Cheaper than median
P/B 6.87× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.58× · Cheaper than median
Price / free cash flow (fiscal year) 21.8× · Cheaper than median
EV/EBITDA 18.1× · Pricier than median
PEG 1.00× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 0
FUTURE (revenue growth)40 · sector 38
PAST (return on equity)86 · sector 15
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $208.00 $228.80 +10% vs IQV
WuXi AppTec Co 603259 ¥154.46 ¥164.66 +7% vs IQV
Thermo Fisher Scientific Inc TMO $676.94 $686.04 +1% vs IQV
Danaher Corporation DHR $226.34 $209.18 −8% vs IQV
IDEXX Laboratories, Inc IDXX $670.71 $496.48 −26% vs IQV
Labcorp Holdings LH $363.30 $230.82 −36% vs IQV
Mettler-Toledo International Inc MTD $1,679 $650.28 −61% vs IQV
Agilent Technologies, Inc A $171.78 $64.53 −62% vs IQV
Lonza Group LONN CHF 672.40 CHF 153.50 −77% vs IQV
Waters Corporation WAT $453.08 $91.26 −80% vs IQV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IQVIA Holdings Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "IQVIA Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/IQV

Frequently asked questions

Is IQVIA Holdings Inc (IQV) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $288.85 versus a price of $264.88, about +9% upside (fairly valued).
What is the fair value of IQV?
Our model-based fair value for IQVIA Holdings Inc is $288.85 (as of Nov 4, 2026), built from audited fundamentals. The current price: $264.88.
What is the quality score of IQV?
IQVIA Holdings Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IQVIA Holdings Inc (IQV)?
Our model-based price target is the fair value of $288.85 (as of Nov 4, 2026) from 22 valuation models. Cautious scenario $178.47, optimistic scenario $402.58. It is a calculation from audited fundamentals, not an analyst target.
What is the IQVIA Holdings Inc stock forecast for 2026?
Our models put fair value at $288.85, about +9% upside versus a price of $264.88 (fairly valued). Cautious scenario $178.47, optimistic scenario $402.58. The calculation is refreshed regularly with new filings.
What is the revenue of IQVIA Holdings Inc (IQV)?
IQVIA Holdings Inc reported trailing-twelve-month revenue of about $17.3B (latest available figure, as of Nov 4, 2026).
What growth is priced into IQVIA Holdings Inc (IQV)?
For today's price to be fair in a discounted-cash-flow model, IQVIA Holdings Inc would have to grow free cash flow by +15.9 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of IQV use?
Our models discount IQVIA Holdings Inc at 9.6 %: a base by market capitalisation (large), damped by beta 1.17, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For IQVIA Holdings Inc that is +15.9 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has IQVIA Holdings Inc (IQV) delivered so far?
Over the past 5 years revenue at IQVIA Holdings Inc grew +7.5 % a year. The price currently implies +15.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of IQVIA Holdings Inc (IQV) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into IQVIA Holdings Inc (+15.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of IQVIA Holdings Inc (IQV)?
The free-cash-flow yield on the price is 4.59 %: that much free cash flow IQVIA Holdings Inc produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of IQVIA Holdings Inc (IQV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IQVIA Holdings Inc it is $288.85 per share (as of Nov 4, 2026), against a price of $264.88. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is IQVIA Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, IQV trades below its calculated fair value: price $264.88, fair value $288.85, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IQV?
No. The price is what the market pays today ($264.88); the fair value is what the company's own numbers justify ($288.85). For IQVIA Holdings Inc the two are $23.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is IQVIA Holdings Inc worth?
The market values IQVIA Holdings Inc at about $44.7B (market capitalisation, as of Nov 4, 2026). Per share that is $264.88; our models calculate a fair value of $288.85 per share.
What do the bullish and bearish scenarios say about IQV?
Our models span a range for IQVIA Holdings Inc: cautious scenario $178.47, base $288.85, optimistic $402.58 per share (as of Nov 4, 2026, price $264.88). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IQV?
IQVIA Holdings Inc trades at a price-to-earnings ratio of 32.2 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $288.85 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 46.4. Other multiples: PEG 1.0, P/B 6.9, P/S 2.6, EV/EBITDA 18.1.
What is the PEG ratio of IQV?
The PEG ratio of IQVIA Holdings Inc is 1.00 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of IQVIA Holdings Inc (IQV)?
Balance-sheet figures for IQVIA Holdings Inc (as of Nov 4, 2026): return on equity 21.4%, debt of 2.14 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is IQV from its 52-week high?
IQVIA Holdings Inc trades at $264.88, about 5% below its 52-week high of $279.36 and 69% above the low of $156.66 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $288.85 is for.
Which stocks are comparable to IQVIA Holdings Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IQVIA Holdings Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $264.88, calculated fair value $288.85 (+9%), Quality Score 60/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IQV calculated?
We run IQVIA Holdings Inc through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $288.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. IQVIA Holdings Inc currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IQVIA Holdings Inc (IQV)?
The closing price on Nov 5, 2026 was $264.88. Our model-based fair value is $288.85, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IQVIA Holdings Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($178.47 to $402.58) leaves room in how you read the outcome.
Where does the earnings growth of IQVIA Holdings Inc (IQV) come from?
Earnings per share at IQVIA Holdings Inc grew +15.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.7 %, EBIT margin +3.2 %, tax rate +4.8 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of IQVIA Holdings Inc

How large is the market capitalisation of IQVIA Holdings Inc (IQV)?
The market capitalisation of IQVIA Holdings Inc is $44.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IQVIA Holdings Inc (IQV)?
The price-to-sales ratio of IQVIA Holdings Inc is 2.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IQVIA Holdings Inc (IQV)?
Earnings per share at IQVIA Holdings Inc are $8.22 (price ÷ EPS = P/E 32.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of IQVIA Holdings Inc (IQV)?
The net margin of IQVIA Holdings Inc is 8.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IQVIA Holdings Inc (IQV)?
The return on equity (ROE) of IQVIA Holdings Inc is 21.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IQVIA Holdings Inc (IQV)?
On an EBIT basis the return on assets of IQVIA Holdings Inc is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IQVIA Holdings Inc (IQV)?
The operating margin of IQVIA Holdings Inc is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IQVIA Holdings Inc (IQV)?
Revenue at IQVIA Holdings Inc is growing +8.0% versus a year earlier (3y avg +4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at IQVIA Holdings Inc (IQV)?
Earnings per share at IQVIA Holdings Inc are growing +8.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does IQVIA Holdings Inc (IQV) carry?
The net debt of IQVIA Holdings Inc is $14.2B (fiscal year 2025, ≈ 6.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch IQVIA Holdings Inc in the live analysis

One click puts IQVIA Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.